Letter to the Editor

Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

Published online:
  • Subscribe to Leukemia for full access:

    $1031

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

References

  1. 1.

    , , . Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030–1043.

  2. 2.

    , , , , , et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269–271.

  3. 3.

    , , , , , et al. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. Blood 2010; 115: 1735–1745.

  4. 4.

    , , , , , et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood 2014; 123: 1040–1050.

  5. 5.

    , , . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.

  6. 6.

    , , . Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Investig New Drugs 2010; 28: S3–20.

  7. 7.

    , , , , , et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci USA 2007; 104: 8071–8076.

  8. 8.

    , , , , , et al. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. Leukemia 2012; 26: 1517–1526.

  9. 9.

    , , , , , et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697–3702.

  10. 10.

    , , , , , et al. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Oncogene 2010; 29: 5957–5968.

  11. 11.

    , , , , , . Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1. Mol Cell Biol 2000; 20: 7505–7515.

  12. 12.

    , , , , , et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature 2016; 538: 518–522.

  13. 13.

    , , , , , et al. Manipulation of B-cell responses with histone deacetylase inhibitors. Nat Commun 2015; 6: 6838.

  14. 14.

    , , , , , et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331–2337.

  15. 15.

    , , , , , et al. A Myc-dependent division timer complements a cell-death timer to regulate T cell and B cell responses. Nat Immunol 2017; 18: 96–103.

  16. 16.

    , , , , , et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol 2015; 2: e326–e333.

Download references

Acknowledgements

The work was funded by the Australian National Health and Medical Research Council. MW was supported by a fellowship from the Deutsche Forschungsgemeinschaft and funding from the NHMRC. SJV was funded by a Rubicon fellowship from the Netherlands Organization for Scientific Research. EDH was supported by a fellowship from the National Health and Medical Research Council of Australia. RWJ was supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship, project and program grants from the NHMRC, the Cancer Council Victoria and the Victorian Cancer Agency. EDH would like to thank Sarah Russell for mentorship through the project.

Author contributions

MW, SJV, SH, EDH and RWJ designed the experiments. MW, SJV, IYK, BPM, KMR and EDH performed the experiments. MW, SJV, IYK, BPM, KMR and EDH analyzed the data. MW, SJV, EDH and RWJ wrote the manuscript.

Author information

Author notes

    • M Waibel
    • , S J Vervoort
    • , E D Hawkins
    •  & R W Johnstone

    These authors contributed equally to this work.

Affiliations

  1. Cancer Therapeutics, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    • M Waibel
    • , S J Vervoort
    • , B P Martin
    •  & R W Johnstone
  2. Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

    • M Waibel
    • , S J Vervoort
    • , K M Ramsbottom
    •  & R W Johnstone
  3. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Australia

    • M Waibel
    • , S J Vervoort
    •  & R W Johnstone
  4. The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia and

    • I Y Kong
    • , S Heinzel
    •  & E D Hawkins
  5. Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia

    • I Y Kong
    • , S Heinzel
    •  & E D Hawkins

Authors

  1. Search for M Waibel in:

  2. Search for S J Vervoort in:

  3. Search for I Y Kong in:

  4. Search for S Heinzel in:

  5. Search for K M Ramsbottom in:

  6. Search for B P Martin in:

  7. Search for E D Hawkins in:

  8. Search for R W Johnstone in:

Competing interests

The Johnstone laboratory receives research funding from Novartis for studies involving panobinostat.

Corresponding authors

Correspondence to E D Hawkins or R W Johnstone.

Supplementary information

Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu)